Company news
Allarity Therapeutics, Inc. news in 2023
Allarity Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
December 11, 2023
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
December 4, 2023
Allarity Therapeutics to Present at Biomarkers Europe 2023
October 1, 2023
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
September 13, 2023
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
August 29, 2023
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
July 30, 2023
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
July 23, 2023
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
July 5, 2023
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
July 4, 2023
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
June 27, 2023
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
June 26, 2023
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
June 19, 2023
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
May 29, 2023
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023
April 26, 2023
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
April 18, 2023
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
April 10, 2023
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
March 27, 2023
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
March 19, 2023
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
January 19, 2023
Decks in 2023
- Investor Presentation (December 2023)
Investor deck · 45 slides · Dec 6, 2023
- Investor Presentation (November 2023)
Investor deck · 42 slides · Nov 13, 2023
- Investor Presentation (March 2023)
Investor deck · 37 slides · Mar 9, 2023